Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

Splitit, a global leader in credit card-linked payment installments, announces the launch of its new fully Embedded Shopify App - Splitit Card Installments. This new app provides merchants with an all ...

U.S. stock index futures were slightly higher on Tuesday, as Wall Street looked to extend a rally from the previous session.

Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential. See why I think AQST stock is a buy ...

Sumo Logic, the leading SaaS Log Analytics Platform, today announced its 15-year milestone of transforming how organizations leverage log analytics for security and observability. Founded with a ...

Type 2 diabetes is a common condition that causes high blood sugar levels. Early signs and symptoms are very important to ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...